The Potential Influence of Immune Modulatory Molecules (TGF-βIII and CTLA-4) in Pathogenicity of PCOS

Polycystic ovary syndrome (PCOS) is characterised by chronic anovulation, hyperandrogenism, polycystic ovaries, and immunological dysregulation. Immune homeostasis and inflammation management require immune functions. T-regulatory cells (Tregs) regulate PCOS's immune system, inflammation, insulin resistance, ovarian function, and homeostasis. Transforming growth factor βIII (TGF-βIII) and Cytotoxic-T-lymphocyte-associated-protein-4 (CTLA-4) receptors on the surfaces of Treg cells are important for controlling the immune system. The study included 68 PCOS patients and 22 non-PCOS women controls aged 20–45. The waist-hip ratio (WHR) determines obesity. We evaluated serum levels and gene expression of TGF-βIII and CTLA-4 via ELISA and real-time PCR. Women with PCOS had significantly higher TGF-βIII and CTLA-4 levels compared to controls. The study reveals a considerable increase in TGF-βIII and CTLA-4 gene expression in PCOS patients compared to the control. Compared to controls, PCOS aged 25 had higher serum TGF-III and CTLA-4 concentrations. According to the RT-PCR test, the PCOS (> 25) had much higher amounts of TGF-βIII and CTLA-4 gene expression than the control. TGF-βIII and CTLA-4 also increased WHR at 0.8 compared to the control. The RT-PCR results showed that the obese PCOS had much higher levels of TGF-βIII and CTLA-4 gene expression (>0.8) than the control. Based on clinical signs, serum TGF-βIII levels and folding were significantly higher in women with PCOS who had irregular periods compared to women whose cycles were normal. These data indicate a role for TGF-βIII and CTLA-4 in PCOS etiology. This study suggests targeting TGF-βIII and CTLA-4 for PCOS immunotherapy.